Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence

Journal of Hepatology

Volumn 59, Issue 1, 2013, Pages 3-5

  Toso, Christian ^a   Mentha, Gilles ^a   Majno, Pietro ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB;

CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SKIN MANIFESTATION; TUMOR ENGRAFTMENT;

EID: 84879159210     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.029     Document Type: Editorial

References (20)

1. EASL-EORTC EASL-EORTC clinical practice guidelines management of hepatocellular carcinoma J Hepatol 56 2012 908 943
2. C. Sposito, L. Mariani, A. Germini, M.F. Reyes, M. Bongini, and G.G. Grossi Comparative efficacy of sorafenib vs. best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study J Hepatol 59 2013 59 66
3. C. Toso, G. Mentha, and P. Majno Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence Am J Transplant 11 2011 2031 2035
4. C. Toso, S. Cader, A. Mentha-Dugerdil, G. Meeberg, P. Majno, and I. Morard Factors predicting survival after post-transplant hepatocellular carcinoma recurrence J Hepatobiliary Pancreat Sci 20 2013 342 347
5. M. Vivarelli, A. Cucchetti, G. La Barba, M. Ravaioli, M. Del Gaudio, and A. Lauro Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence Ann Surg 248 2008 857 862
6. C. Toso, S. Merani, D.L. Bigam, A.M. Shapiro, and N.M. Kneteman Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma Hepatology 51 2010 1237 1243
7. A. Kornberg, B. Kupper, A. Tannapfel, K. Katenkamp, K. Thrum, and O. Habrecht Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables Eur J Surg Oncol 36 2010 275 280
8. S. Hwang, Y.H. Kim, D.K. Kim, C.S. Ahn, D.B. Moon, and K.H. Kim Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation World J Surg 36 2012 1592 1602
9. C. Gomez-Martin, J. Bustamante, J.F. Castroagudin, M. Salcedo, E. Garralda, and M. Testillano Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation Liver Transpl 18 2012 45 52
10. S. Bhoori, S. Toffanin, C. Sposito, A. Germini, A. Pellegrinelli, and A. Lampis Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle J Hepatol 52 2010 771 775
11. P. Newell, S. Toffanin, A. Villanueva, D.Y. Chiang, B. Minguez, and L. Cabellos Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 2009 725 733
12. T.C. Gangadhar, E.E. Cohen, K. Wu, L. Janisch, D. Geary, and M. Kocherginsky Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies Clin Cancer Res 17 2011 1956 1963
13. C. Zavaglia, A. Airoldi, A. Mancuso, M. Vangeli, R. Vigano, and G. Cordone Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature Eur J Gastroenterol Hepatol 25 2013 180 186
14. K. Staufer, L. Fischer, B. Seegers, E. Vettorazzi, B. Nashan, and M. Sterneck High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation Transpl Int 25 2012 1158 1164
15. A. Weinmann, I.M. Niederle, S. Koch, M. Hoppe-Lotichius, M. Heise, and C. Duber Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation Dig Liver Dis 44 2012 432 437
16. A.C. Piguet, B. Saar, R. Hlushchuk, M.V. St-Pierre, P.M. McSheehy, and V. Radojevic Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma Mol Cancer Ther 10 2011 1007 1017
17. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829
18. O. Waidmann, W.P. Hofmann, S. Zeuzem, and J. Trojan MTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation J Hepatol 54 2011 396 398
19. J. Yan, C. Tan, F. Gu, J. Jiang, M. Xu, and X. Huang Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of pERK Liver Transpl 2013 in press
20. S. Saab, M. McTigue, R.S. Finn, and R.W. Busuttil Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy Exp Clin Transplant 8 2010 307 313